Abstract
The numbers of people with type 2 diabetes are rising rapidly around the world, making it imperative to develop and introduce methods of preventing the condition. A series of clinical trials over the last decade has shown conclusively that lifestyle interventions focusing on physical activity, diet, and weight loss can reduce the risk of developing type 2 diabetes by approximately 60%. Trials examining pharmaceutical interventions have shown that metformin, acarbose, and glitazones also reduce the risk of developing diabetes, but have shown no benefit of ACE inhibitors. Although uncertainty remains about the widespread use of pharmaceutical agents for diabetes prevention, programmes to implement lifestyle changes in those at high risk of developing type 2 diabetes now need to be put in place.
Keywords
- Impaired Glucose Tolerance
- Angiotensin Converting Enzyme Inhibitor
- Lifestyle Intervention
- Impaired Fasting Glucose
- Diabetes Prevention
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Sicree R, Shaw JE, Zimmet PZ: Diabetes and impaired glucose tolerance. In Diabetes Atlas, 3rd ed. Gan D, Ed. Brussels, International Diabetes Federation, 2006, 10–149.
Riste L, Khan F, Cruickshank K: High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity, or 21st century Europe? Diabetes Care 24:1377–1383, 2001.
Soderberg S, Zimmet P, Tuomilehto J, de Courten M, Dowse GK, Chitson P, Gareeboo H, Alberti KG, Shaw JE: Increasing prevalence of type 2 diabetes mellitus in all ethnic groups in Mauritius. Diabetes Med 22:61–68, 2005.
Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, Rao PV, Yajnik CS, Prasannakumar KM, Nair JD: High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 44:1094–1101, 2001.
Sadikot SM, Nigam A, Das S, Bajaj S, Zargar AH, Prasannakumar KM, Sosale A, Munichoodappa C, Seshiah V, Singh SK, Jamal A, Sai K, Sadasivrao Y, Murthy SS, Hazra DK, Jain S, Mukherjee S, Bandyopadhay S, Sinha NK, Mishra R, Dora M, Jena B, Patra P, Goenka K: The burden of diabetes and impaired glucose tolerance in India using the WHO 1999 criteria: prevalence of diabetes in India study (PODIS). Diabetes Res Clin Pract 66:301–307, 2004.
Salme ron J, Hu FB, Manson JE, Stampfer MJ, Colditz GA, Rimm EB, Willett WC: Dietary fat intake and risk of type 2 diabetes in women. Am J Clin Nutr 73:1019–1026, 2001.
Salmerón J, Manson JE, Stampfer MJ, Colditz GA, Wing AL, Willet WC: Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA 277:472–477, 1997.
Perry I, Wannamethee S, Walker M, Thomson AG, Whincup PH, Shaper AG: Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. Br J Med 310:560–564, 1995.
O'Dea K: Marked improvement in carbohydrate and lipid metabolism in diabetic Australian aborigines after temporary reversion to traditional lifestyle. Diabetes 33:596–603, 1984.
Sartor G, Scherstén B, Carlström S, Melander A, Nordén Å, Persson G: Ten-year follow-up of subjects with impaired glucose tolerance. Prevention of diabetes by tolbutamide and diet regulation. Diabetes 29:41–49, 1980.
Bourn D, Mann J, McSkimming B, Waldron M, Wishart J: Impaired glucose tolerance and NIDDM: does a lifestyle intervention have and effect? Diabetes Care 17:1311–1319, 1994.
Torjesen P, Birkeland K, Anderssen S, Hjermann I, Holme I, Urdal P: Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo diet and exercise study: a randomized trial. Diabetes Care 20:26–31, 1997.
Eriksson KF, Lindgarde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 34:891–898, 1991.
Pan X, Li G, Hu Y, Wang J, Yang W, An Z, Hu Z, Lin J, Xiao J, Cao H, Liu P, Jiang X, Wang J, Zheng H, Zhang H, Bennett P, Howard B: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study. Diabetes Care 20:537–544, 1997.
Tuomilehto J, Lindstrom J, Eriksson J, Valle T, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V: Finnish Diabetes Prevention Study Group: prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350, 2001.
Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368:1673–1679, 2006.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403, 2002.
Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J: Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29:2102–2107, 2006.
Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V: The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289–297, 2006.
Kosaka K, Noda M, Kuzuya T: Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 67:152–162, 2005.
Long S, O'Brien K, MacDonald K, Leggett-Frazier N, Swanson M, Pories W, Caro J: Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal intervention study. Diabetes Care 17:372–375, 1994.
Sjostrom CD, Lissner L, Wedel H, Sjostrom L: Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 7:477–484, 1999.
Dixon JB, O'Brien PE: Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 25:358–363, 2002.
Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:155–161, 2004.
Fajans SS, Conn JW: Tolbutamide-induced improvement in carbohydrate tolerance of young people with mild diabetes mellitus. Diabetes 9:83–88, 1960.
Engelhardt HT, Vecchio TJ: The long-term effect of Tolbutamide on glucose tolerance in adult, asymptomatic, latent diabetics. Metabolism 14:885–890, 1965.
Belknap B, Bagdade J, Amaral J, Bierman E: Plasma lipids and mild glucose intolerance II: a double blind study of the effect of tolbutamide and placebo in mild adult diabetic outpatients. Excepta Med Int Congr Ser 149:171–176, 1967.
Paasikivi J, Wahlberg F: Preventive tolbutamide treatment and arterial disease in mild hyperglycaemia. Diabetologia 7:323–327, 1971.
Keen H, Jarrett R, McCartney P: The ten-year follow-up of the Bedford survey (1962–1972): glucose tolerance and diabetes. Diabetologia 22:73–78, 1982.
Camerini-Davalosra R: Treatment of chemical diabetes. Exepta Med Int Congr Ser 149:228–242, 1967.
Jarrett RJ, Keen H, Fuller JH, McCartney M: Treatment of borderline diabetes: controlled trial using carbohydrate restriction and phenformin. Br Med J 2:861–865, 1977.
Papoz L, Job D, Eschwege E, Aboulker JP, Cubeau J, Pequignot G, Rathery M, Rosselin G: Effect of oral hypoglycaemic drugs on glucose tolerance and insulin secretion in borderline diabetic patients. Diabetologia 15:373–380, 1978.
Ratzmann KP, Witt S, Schulz B: The effect of long-term glibenclamide treatment on glucose tolerance, insulin secretion and serum lipids in subjects with impaired glucose tolerance. Diabete Metab 9:87–93, 1983.
Cederholm J: Short-term treatment of glucose intolerance in middle-aged subjects by diet, exercise and sulfonylurea. Ups J Med Sci 90:229–242, 1985.
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077, 2002.
Diabetes Prevention Program Research Group: Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 26:977–980, 2003.
Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE: Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54:1150–1156, 2005.
Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51:2796–2803, 2002.
Wenying Y, Lixiang L, Jinwu Q, Zhiqing Y, Haicheng P, Guofeng H, Zaojun Y, Fan W, Guangwei L, Xiaoren P: The preventive effect of Acarbose and Metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study. Chin J Endocrinol Metab 17:131–136, 2001.
Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B: Ramipril and the development of diabetes. JAMA 286:1882–1885, 2001.
Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR: Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551–1562, 2006.
Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096–1105, 2006.
Wylie-Rosett J, Herman WH, Goldberg RB: Lifestyle intervention to prevent diabetes: intensive and cost effective. Curr Opin Lipidol 17:37–44, 2006.
Shaw J, Zimmet P, de Courten M, Dowse G, Chitson P, Gareeboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti K: Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 22:399–402, 1999.
Vartiainen E, Jousilahti P, Alfthan G, Sundvall J, Pietinen P, Puska P: Cardiovascular risk factor changes in Finland, 1972–1997. Int J Epidemiol 29:49–56, 2000.
Uusitalo U, Feskens E, Tuomilehto J, Dowse G, Haw U, Fareed D, Hemraj F, Gareeboo H, Alberti K, Zimmet P: Fall in total cholesterol concentration over five years in association with changes in fatty acid composition of cooking oil in Mauritius: cross sectional survey. BMJ 313:1044–1046, 1996.
Home PD , Pocock SJ , Beck-Nielsen H , et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) Study: interim findings on cardovascular hospitalizations and deaths. N Engl J Med 357 : 28–38 , 2007
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Shaw, J.E., Simpson, R.W. (2009). Prevention of Type 2 Diabetes. In: Regensteiner, J.G., Reusch, J.E., Stewart, K.J., Veves, A. (eds) Diabetes and Exercise. Contemporary Diabetes. Humana Press. https://doi.org/10.1007/978-1-59745-260-1_2
Download citation
DOI: https://doi.org/10.1007/978-1-59745-260-1_2
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-58829-926-0
Online ISBN: 978-1-59745-260-1
eBook Packages: MedicineMedicine (R0)